STOCK TITAN

ViewRay Announces Participation in the B. Riley Oncology Investor Conference

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

CLEVELAND, Jan. 15, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) (the "Company") today announced that members of management will be participating in a fireside chat at the B. Riley Oncology Investor Conference on Wednesday, January 20, 2021. ViewRay will also be hosting 1x1 meetings with investors.

An audio recording of the fireside chat will be available after the event on the "Financial Events and Webinars" portion of ViewRay's investor website at https://investors.viewray.com/events-and-presentations/upcoming-events. The recording will be available for 7 days after the date of the presentation.

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Cision View original content:http://www.prnewswire.com/news-releases/viewray-announces-participation-in-the-b-riley-oncology-investor-conference-301209021.html

SOURCE ViewRay, Inc.

ViewRay Inc.

NASDAQ:VRAY

VRAY Rankings

VRAY Latest News

VRAY Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Oakwood Village

About VRAY

mri-guided adaptive radiotherapy viewray®, inc. (nasdaq:vray), designs, manufactures, and markets the mridian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. mridian employs mri-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. mridian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. viewray believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. at viewray, our vision is clear. we’re dedicated to giving doctors new and better ways to treat cancer with radiation therapy. we’re an entrepreneurial company with big ambitions, unlimited potential and a passion for improving